LACTOLOGY FOUNDATION

A07XA02 Ceratonia: Toxicological and Lactological Monograph

ATC Class and General Pharmacology

Ceratonia is classified as A07XA02 in the WHO Anatomical Therapeutic Chemical system, within A07XA, Other antidiarrheals, and the broader A07 group, Antidiarrheals, intestinal anti-inflammatory/anti-infective agents. In this context, Ceratonia refers principally to preparations derived from Ceratonia siliqua L., commonly known as carob.atcddd.fhi

Carob preparations used for diarrhoea are generally derived from the pod pulp or pod fractions and can contain dietary fibre, sugars, polyphenols, condensed tannins, and other plant constituents. Their antidiarrhoeal effect is considered predominantly gastrointestinal and multifactorial. The principal proposed mechanisms include an astringent action of tannins on the intestinal mucosa, binding or interaction with luminal substances, increased stool bulk through fibre content, reduced stool water content, and possible modification of intestinal secretion or mucosal inflammation. Carob-derived tannins have been associated with antidiarrhoeal activity in experimental and clinical nutrition contexts.pmc.ncbi.nlm.nih+1

The pharmacological activity of a Ceratonia preparation cannot be assumed to be identical across all products. Pod powder, aqueous extracts, hydroalcoholic or methanolic extracts, soluble fibre preparations, tannin-enriched fractions, food products, and multi-ingredient supplements may differ substantially in phytochemical composition, tannin concentration, fibre content, dose, bioavailability, and clinical effect. Consequently, an ATC classification as A07XA02 does not establish equivalence among all carob-containing products.

Ceratonia products are supportive symptomatic treatments and do not replace oral rehydration, electrolyte correction, microbiological assessment, or treatment of the underlying cause of diarrhoea. Their use should be limited to clinically appropriate situations, particularly when diarrhoea is uncomplicated and self-limiting.

Toxicological Profile

The toxicological profile of Ceratonia-based antidiarrhoeal products is influenced by the plant part used, extraction method, standardisation, dose, duration, co-administered medicines, nutritional status, and individual susceptibility. Carob has a long history of dietary use, and short-term ingestion of conventional food-derived preparations is generally well tolerated. However, medicinal use—especially of concentrated extracts or tannin-rich products—requires a more cautious toxicological interpretation.

Potential adverse effects include constipation, abdominal discomfort, bloating, nausea, altered stool consistency, and excessive stool thickening. The high fibre content of some preparations can cause gastrointestinal symptoms, especially when introduced rapidly or used in large amounts. Carob may also produce clinically relevant reactions in individuals with hypersensitivity to carob or related plant-derived components; serious allergic reactions, although uncommon, remain possible.webmd

Tannin-rich preparations may reduce the bioavailability of nutrients, minerals, or concomitant orally administered medicines through complex formation, adsorption, or intestinal binding. This interaction potential is particularly relevant during prolonged treatment, high intake, malnutrition, iron deficiency, polypharmacy, or use of medicines with narrow therapeutic ranges. Administration at a different time from essential oral medicines is a reasonable precaution when using tannin-containing carob products.

Additional toxicological considerations include:

• Product variability: Botanical preparations may differ in their identity, purity, extraction solvent, tannin content, microbial quality, pesticide residues, heavy-metal contamination, and undeclared constituents.
• Glycaemic effects: Carob-containing products may contain appreciable carbohydrates, while some reports suggest possible glucose-lowering activity. Caution is appropriate in individuals using glucose-lowering therapies or in those with unstable glycaemic control.webmd
• Constipation risk: Excessive astringent or fibre effects may worsen constipation, especially in susceptible individuals or when fluid intake is inadequate.
• Nutritional implications: Prolonged use of high-tannin preparations may be undesirable in persons with poor nutritional intake or risk of micronutrient deficiency.
• Clinical masking: Persistent, bloody, febrile, severe, or dehydration-associated diarrhoea requires diagnostic evaluation and should not be managed with prolonged symptomatic botanical treatment.

Available animal data on selected carob extracts have not identified acute toxicity at high administered doses; however, these findings cannot be directly extrapolated to breastfeeding women, infants, commercial formulations, chronic exposure, or concentrated tannin-rich extracts.link.springer

Lactation Pharmacology and Infant Exposure

Direct data on transfer of Ceratonia-derived constituents, carob tannins, or standardised carob extracts into human breast milk are insufficient. There are no robust milk-concentration studies, relative infant dose estimates, infant serum-level studies, or controlled breastfeeding outcome datasets that establish the safety of medicinal Ceratonia products during lactation.

The lactation assessment therefore relies mainly on pharmacokinetic plausibility and formulation-specific considerations. Many relevant components of carob—especially high-molecular-weight tannins and non-absorbed fibre fractions—are expected to have limited maternal systemic bioavailability after oral use. If maternal plasma exposure is negligible, meaningful transfer into human milk is unlikely. Furthermore, many polyphenolic complexes and fibre-associated constituents would be expected to have low oral bioavailability in the infant.

Nevertheless, carob is a complex botanical material rather than a single well-defined pharmaceutical molecule. Lower-molecular-weight phenolic compounds, soluble constituents, sugars, metabolites, and co-formulated ingredients may be absorbed to varying degrees and could theoretically enter milk. The uncertainty is greater for concentrated extracts, non-standardised supplements, hydroalcoholic products, multi-ingredient antidiarrhoeal remedies, and products marketed outside conventional medicinal quality standards.

Potential infant exposure is expected to be lowest when the breastfeeding mother uses a short course of a standardised, single-ingredient carob pod preparation at the recommended dose. Risk assessment should be more conservative where maternal therapy is prolonged or high-dose, where the formulation is unknown, or where the infant is premature, newborn, growth-restricted, medically unstable, or affected by renal, hepatic, metabolic, or gastrointestinal disease.

If maternal use is necessary, observe the infant for poor feeding, vomiting, unusual constipation or diarrhoea, abdominal distension, rash, wheeze, irritability, lethargy, reduced urine output, or inadequate weight gain. Such symptoms are not specific for exposure through milk, but they justify paediatric assessment if clinically significant.

Lactological Safety Assessment and Clinical Recommendations

Ceratonia (A07XA02) should be regarded as a low-to-uncertain lactation-risk botanical antidiarrhoeal, rather than as a medicine with established lactation safety. Low exposure is pharmacokinetically plausible for conventional, orally administered, short-term, locally acting carob pod preparations. However, direct evidence from human milk studies and well-described infant outcomes is inadequate, and the variability of botanical formulations prevents a universal safety conclusion.

For a healthy breastfeeding mother with uncomplicated acute diarrhoea, continuation of breastfeeding is generally appropriate. The Centers for Disease Control and Prevention advises that mothers with food- or water-borne diarrhoeal illness can continue breastfeeding while increasing fluid intake; relevant causative organisms do not pass through breast milk in the usual manner. Maternal hydration, electrolyte replacement, hand hygiene, and evaluation for red flags remain more important than symptomatic treatment.cdc

Clinical recommendations are as follows:

1. Prioritise oral rehydration and cause-directed assessment. Treat dehydration and electrolyte losses promptly. A carob preparation is adjunctive treatment, not a replacement for oral rehydration or medical evaluation.
2. Use only a standardised, clearly labelled product. Prefer a single-ingredient medicinal or food-grade preparation with defined composition. Avoid unregulated extracts, unknown botanical mixtures, essential-oil products, and combination remedies during breastfeeding.
3. Use the lowest effective dose for the shortest duration. Avoid prolonged, repeated, or high-dose self-treatment. Persistent symptoms require reassessment of diagnosis and management.
4. Consider drug and nutrient interactions. Separate administration from important oral medicines when feasible, particularly iron supplements, thyroid hormone, antiepileptics, immunosuppressants, anticoagulants, and other drugs where reduced absorption could be clinically consequential.
5. Continue breastfeeding when maternal status allows. Maternal uncomplicated diarrhoea is not, by itself, an indication to interrupt breastfeeding. Increase maternal fluid intake and use meticulous hand hygiene after toileting and before handling food or feeding equipment.cdc+1
6. Avoid use or obtain specialist advice in higher-risk scenarios. This includes prolonged treatment, concentrated extracts, uncertain formulations, concurrent use of hypoglycaemic medication, maternal malnutrition, significant renal or hepatic disease, and breastfeeding of a premature or medically vulnerable infant.
7. Monitor the infant and seek care for warning signs. Paediatric assessment is appropriate for poor feeding, dehydration, persistent gastrointestinal symptoms, rash, respiratory symptoms, lethargy, or poor weight gain. Maternal medical review is needed for high fever, blood in stool, severe pain, significant dehydration, reduced urine output, inability to maintain oral intake, or ongoing diarrhoea.